StockNews.com Begins Coverage on Athersys (NASDAQ:ATHX)

StockNews.com initiated coverage on shares of Athersys (NASDAQ:ATHX) in a research note issued to investors on Saturday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Athersys Stock Down 33.5 %

ATHX opened at $0.01 on Friday. The firm has a market capitalization of $833,206.50, a price-to-earnings ratio of -0.01 and a beta of -0.90. Athersys has a 1-year low of $0.01 and a 1-year high of $1.99.

Athersys Company Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.